is ozempic a glp-1 drug first FDA-approved for kidney disease Unusual" Side Effect of Ozempic-Like
Description
Amgen, Inc
)
Hurtado M et al
Science 270: 11661170
35 The recent phase 3 Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis (ESSENCE) trial showed that semaglutide 2.4 mg once weekly improved liver histology in patients with metabolic dysfunction-associated steatohepatitis with moderate or advanced liver fibrosis
Januvia [package insert]
However, establishing causality in pharmacovigilance is inherently challenging, as temporal association does not prove causation
